Cargando…

Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing

BACKGROUND: India has a large number of HIV infected patients being followed up at anti-retroviral therapy (ART) centers. The patients are regularly offered CD4 count estimation for deciding their eligibility for ART initiation as well as for monitoring response to ART, making CD4 count estimation a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shete, Ashwini, Singh, Dharmesh P, Mahajan, Bharati, Kokare, Amol, Paranjape, Ramesh, Thakar, Madhuri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536604/
https://www.ncbi.nlm.nih.gov/pubmed/26279667
http://dx.doi.org/10.1186/s12981-015-0067-6
_version_ 1782385764422647808
author Shete, Ashwini
Singh, Dharmesh P
Mahajan, Bharati
Kokare, Amol
Paranjape, Ramesh
Thakar, Madhuri
author_facet Shete, Ashwini
Singh, Dharmesh P
Mahajan, Bharati
Kokare, Amol
Paranjape, Ramesh
Thakar, Madhuri
author_sort Shete, Ashwini
collection PubMed
description BACKGROUND: India has a large number of HIV infected patients being followed up at anti-retroviral therapy (ART) centers. The patients are regularly offered CD4 count estimation for deciding their eligibility for ART initiation as well as for monitoring response to ART, making CD4 count estimation a very critical test. Hence, quality control of CD4 testing is utmost important for ultimate success of ART program. As the commercial controls are very expensive, internal quality control (IQC), at present, is being done by duplicate analysis method using previous day samples in most of the laboratories. Hence the study was undertaken to review performance of duplicate analysis method for monitoring daily IQC. METHODS: Quality control (QC) data from 11 Indian laboratories using duplicate analysis and/or commercial controls for IQC of CD4 testing was collected for reviewing information on QC parameters such as precision, accuracy and trend monitoring. Precision was determined by r(2) values and mean % variation for duplicate analysis and coefficient of variation (% CV) for commercial controls. Accuracy was monitored by rate of QC failures for both the types of control and trend monitoring was done by plotting LJ charts for commercial controls and by plotting daily % variation for duplicate analysis. RESULTS: The laboratories using duplicate analysis for IQC showed good precision with mean % variation ranging from 0.5 to 7.2. There was good match between r(2) values and % CV of the laboratories performing both the types of QC methods. Rates of QC failures were 2.3 for duplicate analysis and 3 per laboratory-year for IMMUNO-TROL controls. Daily trend monitoring showed fluctuation of daily counts around mean in LJ charts and of percent variation around 0% in duplicate analysis method. Commercially available controls showed limitations such as altered specimen quality leading to difficulties in manual gating and issues with the establishment of laboratory range. CONCLUSION: Duplicate analysis can serve as a cheaper alternative to commercially available controls for IQC of CD4 testing especially when supplemented with other QC measures for controlling variations caused by reagent, equipment, staff and environment in addition to the successful participation in External Quality Assurance programme.
format Online
Article
Text
id pubmed-4536604
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45366042015-08-15 Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing Shete, Ashwini Singh, Dharmesh P Mahajan, Bharati Kokare, Amol Paranjape, Ramesh Thakar, Madhuri AIDS Res Ther Research BACKGROUND: India has a large number of HIV infected patients being followed up at anti-retroviral therapy (ART) centers. The patients are regularly offered CD4 count estimation for deciding their eligibility for ART initiation as well as for monitoring response to ART, making CD4 count estimation a very critical test. Hence, quality control of CD4 testing is utmost important for ultimate success of ART program. As the commercial controls are very expensive, internal quality control (IQC), at present, is being done by duplicate analysis method using previous day samples in most of the laboratories. Hence the study was undertaken to review performance of duplicate analysis method for monitoring daily IQC. METHODS: Quality control (QC) data from 11 Indian laboratories using duplicate analysis and/or commercial controls for IQC of CD4 testing was collected for reviewing information on QC parameters such as precision, accuracy and trend monitoring. Precision was determined by r(2) values and mean % variation for duplicate analysis and coefficient of variation (% CV) for commercial controls. Accuracy was monitored by rate of QC failures for both the types of control and trend monitoring was done by plotting LJ charts for commercial controls and by plotting daily % variation for duplicate analysis. RESULTS: The laboratories using duplicate analysis for IQC showed good precision with mean % variation ranging from 0.5 to 7.2. There was good match between r(2) values and % CV of the laboratories performing both the types of QC methods. Rates of QC failures were 2.3 for duplicate analysis and 3 per laboratory-year for IMMUNO-TROL controls. Daily trend monitoring showed fluctuation of daily counts around mean in LJ charts and of percent variation around 0% in duplicate analysis method. Commercially available controls showed limitations such as altered specimen quality leading to difficulties in manual gating and issues with the establishment of laboratory range. CONCLUSION: Duplicate analysis can serve as a cheaper alternative to commercially available controls for IQC of CD4 testing especially when supplemented with other QC measures for controlling variations caused by reagent, equipment, staff and environment in addition to the successful participation in External Quality Assurance programme. BioMed Central 2015-08-14 /pmc/articles/PMC4536604/ /pubmed/26279667 http://dx.doi.org/10.1186/s12981-015-0067-6 Text en © Shete et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Shete, Ashwini
Singh, Dharmesh P
Mahajan, Bharati
Kokare, Amol
Paranjape, Ramesh
Thakar, Madhuri
Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing
title Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing
title_full Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing
title_fullStr Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing
title_full_unstemmed Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing
title_short Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing
title_sort duplicate analysis method: a cheaper alternative to commercial iqc materials in limited resource settings for monitoring cd4 testing
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536604/
https://www.ncbi.nlm.nih.gov/pubmed/26279667
http://dx.doi.org/10.1186/s12981-015-0067-6
work_keys_str_mv AT sheteashwini duplicateanalysismethodacheaperalternativetocommercialiqcmaterialsinlimitedresourcesettingsformonitoringcd4testing
AT singhdharmeshp duplicateanalysismethodacheaperalternativetocommercialiqcmaterialsinlimitedresourcesettingsformonitoringcd4testing
AT mahajanbharati duplicateanalysismethodacheaperalternativetocommercialiqcmaterialsinlimitedresourcesettingsformonitoringcd4testing
AT kokareamol duplicateanalysismethodacheaperalternativetocommercialiqcmaterialsinlimitedresourcesettingsformonitoringcd4testing
AT paranjaperamesh duplicateanalysismethodacheaperalternativetocommercialiqcmaterialsinlimitedresourcesettingsformonitoringcd4testing
AT thakarmadhuri duplicateanalysismethodacheaperalternativetocommercialiqcmaterialsinlimitedresourcesettingsformonitoringcd4testing